[go: up one dir, main page]

PL2533817T3 - Ukierunkowane kompleksy emitujące cząstki alfa zawierające radionuklid toru i hydroksypirydynon zawierający ligand - Google Patents

Ukierunkowane kompleksy emitujące cząstki alfa zawierające radionuklid toru i hydroksypirydynon zawierający ligand

Info

Publication number
PL2533817T3
PL2533817T3 PL11702857T PL11702857T PL2533817T3 PL 2533817 T3 PL2533817 T3 PL 2533817T3 PL 11702857 T PL11702857 T PL 11702857T PL 11702857 T PL11702857 T PL 11702857T PL 2533817 T3 PL2533817 T3 PL 2533817T3
Authority
PL
Poland
Prior art keywords
hydroxypyridinone
containing ligand
particle emitting
emitting complexes
targeted alpha
Prior art date
Application number
PL11702857T
Other languages
English (en)
Inventor
Thomas Ramdahl
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of PL2533817T3 publication Critical patent/PL2533817T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL11702857T 2010-02-12 2011-02-14 Ukierunkowane kompleksy emitujące cząstki alfa zawierające radionuklid toru i hydroksypirydynon zawierający ligand PL2533817T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1002508.8A GB201002508D0 (en) 2010-02-12 2010-02-12 Product
EP11702857.1A EP2533817B1 (en) 2010-02-12 2011-02-14 Targeted alpha-particle emitting complexes comprising thorium radionuclide and hydroxypyridinone containing ligand
PCT/EP2011/052158 WO2011098611A2 (en) 2010-02-12 2011-02-14 Alpha-emitting complexes

Publications (1)

Publication Number Publication Date
PL2533817T3 true PL2533817T3 (pl) 2018-08-31

Family

ID=42110714

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11702857T PL2533817T3 (pl) 2010-02-12 2011-02-14 Ukierunkowane kompleksy emitujące cząstki alfa zawierające radionuklid toru i hydroksypirydynon zawierający ligand
PL18163914T PL3417883T3 (pl) 2010-02-12 2011-02-14 Ukierunkowane kompleksy emitujące cząstki alfa zawierające radionuklid toru i ligand zawierający hydroksypirydynon

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18163914T PL3417883T3 (pl) 2010-02-12 2011-02-14 Ukierunkowane kompleksy emitujące cząstki alfa zawierające radionuklid toru i ligand zawierający hydroksypirydynon

Country Status (27)

Country Link
US (2) US9724436B2 (pl)
EP (2) EP3417883B1 (pl)
JP (2) JP5878483B2 (pl)
KR (1) KR101931382B1 (pl)
CN (1) CN103608043B (pl)
AU (1) AU2011214281B2 (pl)
BR (1) BR112012020304B1 (pl)
CA (1) CA2789433C (pl)
CY (1) CY1120362T1 (pl)
DK (2) DK2533817T3 (pl)
EA (1) EA026305B1 (pl)
ES (2) ES2674875T3 (pl)
GB (1) GB201002508D0 (pl)
HR (2) HRP20180996T1 (pl)
HU (2) HUE049465T2 (pl)
IL (2) IL221416A (pl)
LT (2) LT2533817T (pl)
MX (1) MX343405B (pl)
NZ (1) NZ601867A (pl)
PL (2) PL2533817T3 (pl)
PT (2) PT2533817T (pl)
RS (2) RS57360B1 (pl)
SG (1) SG183279A1 (pl)
SI (2) SI3417883T1 (pl)
SM (1) SMT201800325T1 (pl)
TR (1) TR201809149T4 (pl)
WO (1) WO2011098611A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2511266B1 (en) 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2816038B8 (en) 2009-08-24 2019-12-25 Lumiphore, Inc. Hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
JP6468602B2 (ja) 2013-01-14 2019-02-13 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド トリアジン系放射性医薬品及び放射線造影剤
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
GB201310028D0 (en) 2013-06-05 2013-07-17 Algeta Asa Pharmaceutical preparation
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
AU2015369722A1 (en) * 2014-12-22 2017-08-03 Lumiphore, Inc. Functionalized linear ligands and complexes thereof
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
SG11201806548UA (en) * 2016-03-24 2018-08-30 Bayer Pharma AG Radio-pharmaceutical complexes
KR20190016544A (ko) * 2016-06-10 2019-02-18 바이엘 파마 악티엔게젤샤프트 방사성-제약 복합체
US20200016283A1 (en) 2017-02-24 2020-01-16 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
FI3498308T3 (fi) 2017-12-13 2025-02-05 Sciencons AS Kompleksi, joka käsittää lyijy- tai toriumradionuklidiin sitoutunutta psma:han kohdentuvaa yhdistettä
WO2020043617A1 (en) 2018-08-28 2020-03-05 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
US12194111B2 (en) 2018-10-16 2025-01-14 Nant Holdings Ip, Llc Alpha emitter compositions and methods
CA3130747A1 (en) 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
CA3130809A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
US20230072421A1 (en) 2019-07-25 2023-03-09 Bayer As Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
EP4281477A2 (en) 2021-01-22 2023-11-29 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
WO2025137443A1 (en) 2023-12-22 2025-06-26 Rayzebio, Inc. Radiopharmaceutical compositions targeting somatostatin receptors and uses thereof
US20250222146A1 (en) 2023-12-22 2025-07-10 Rayzebio, Inc. Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416033B1 (en) 1988-05-25 1996-03-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Macrocyclic chelates and methods of use thereof
DK0429624T3 (da) 1989-06-19 1994-05-30 Akzo Nobel Nv Radioimmunterapi under anvendelse af alfa-partikelemission
JPH07505886A (ja) 1992-04-13 1995-06-29 ザ　ダウ　ケミカル　カンパニー マクロ環状キレート化剤の製造方法及びキレートの形成並びにその結合体
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
AU2865995A (en) * 1995-06-14 1997-01-15 Regents Of The University Of California, The 3-hydroxy-2(1h)-pyridinone chelating agents
CA2269060C (en) 1996-10-17 2009-04-07 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO1998027209A1 (en) 1996-12-18 1998-06-25 Emory University Polycationic oligomers
NO310544B1 (no) 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
EP1227849A2 (en) 2000-02-25 2002-08-07 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
GB0213261D0 (en) 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
US20030228256A1 (en) 2002-06-11 2003-12-11 Inverardi Luca A. Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations
US20030086868A1 (en) 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
ITMI20022411A1 (it) 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
ZA200507983B (en) * 2003-04-15 2007-03-28 Algetaas Thorium-227 for use in radiotherapy of soft tissue disease
US20060228297A1 (en) 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease
US8142758B2 (en) 2004-02-20 2012-03-27 Algeta As Alpha-emitting hydroxyapatite particles
EP2497501B1 (en) * 2004-06-25 2019-05-01 The European Union, represented by the European Commission Radionuclides for medical use
GB0423565D0 (en) 2004-10-22 2004-11-24 Algeta As Formulation
EP2511266B1 (en) * 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
JP5352460B2 (ja) 2006-08-15 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ルミネッセント大環状ランタニド錯体
WO2008085064A2 (en) * 2007-01-11 2008-07-17 Ge Healthcare As Hydroxypyridinone chelating agents, their metal complexes and their use as mri contrast agents
JP2013515744A (ja) * 2009-12-24 2013-05-09 ルミフォア，インコーポレイテッド 放射性医薬品錯体
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201007353D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
WO2011098611A2 (en) 2011-08-18
PL3417883T3 (pl) 2020-08-24
AU2011214281A1 (en) 2012-08-30
JP6125599B2 (ja) 2017-05-10
SI2533817T1 (en) 2018-08-31
GB201002508D0 (en) 2010-03-31
EA026305B1 (ru) 2017-03-31
TR201809149T4 (tr) 2018-07-23
IL221416A0 (en) 2012-10-31
CY1120362T1 (el) 2019-07-10
EP3417883A1 (en) 2018-12-26
ES2794853T3 (es) 2020-11-19
EP2533817B1 (en) 2018-03-28
US10682430B2 (en) 2020-06-16
SMT201800325T1 (it) 2018-09-13
MX343405B (es) 2016-11-03
MX2012009260A (es) 2013-02-07
EA201290712A1 (ru) 2014-12-30
SG183279A1 (en) 2012-09-27
PT2533817T (pt) 2018-06-29
RS57360B1 (sr) 2018-08-31
ES2674875T3 (es) 2018-07-04
HUE038013T2 (hu) 2018-09-28
CN103608043B (zh) 2017-07-28
HRP20180996T1 (hr) 2018-08-10
BR112012020304A2 (pt) 2016-04-26
HRP20200826T1 (hr) 2020-08-07
HUE049465T2 (hu) 2020-09-28
SI3417883T1 (sl) 2020-07-31
LT3417883T (lt) 2020-07-10
IL243303A (en) 2017-09-28
WO2011098611A3 (en) 2015-07-02
NZ601867A (en) 2014-11-28
DK2533817T3 (en) 2018-07-16
US9724436B2 (en) 2017-08-08
US20130183235A1 (en) 2013-07-18
AU2011214281B2 (en) 2014-01-16
JP2013519658A (ja) 2013-05-30
EP2533817A2 (en) 2012-12-19
BR112012020304B1 (pt) 2019-12-10
RS60314B1 (sr) 2020-07-31
IL221416A (en) 2016-03-31
JP2016029114A (ja) 2016-03-03
CA2789433C (en) 2019-01-15
LT2533817T (lt) 2018-07-10
KR101931382B1 (ko) 2018-12-20
KR20120130769A (ko) 2012-12-03
CN103608043A (zh) 2014-02-26
US20170319721A1 (en) 2017-11-09
JP5878483B2 (ja) 2016-03-08
IL243303A0 (en) 2016-04-21
EP3417883B1 (en) 2020-03-25
PT3417883T (pt) 2020-06-01
DK3417883T3 (da) 2020-06-08
CA2789433A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
SI3417883T1 (sl) Tarčni kompleksi, ki oddajajo delec alfa, ki vsebujejo torijev radionuklid in ligand, ki vsebuje hidroksipiridinon
ZA201406969B (en) Combination therapy with an anti-hyaluronan agent and a tumor-targreted taxane
EP2820630A4 (en) VIRTUAL GUARDING WITH LOCATION AGENT
IL235905A0 (en) Software agent for core layer security
PT2920167T (pt) Compostos de hidrazinil-indol e conjugados
SI3521207T1 (sl) Kapsula za odmerek s črtno kodo
EP2804646A4 (en) MULTI-DOSES SYRINGE AND ASSOCIATED METHOD
IL251974B (en) Antifibrosis compounds and their uses
IL233402B (en) User application for geographic-spatial location information of a released criminal
EP2747839A4 (en) BRACHYTHERAPY DEVICES AND METHOD THEREFOR PROVIDED WITH MICRO-ENCAPED BRACHYTHERAPY MATERIALS
GB201003483D0 (en) Gold complexes
EP2831737A4 (en) SOFTWARE DEVELOPMENT ACTIVITY
GB2505767B (en) A Protection and Carrier System
PL2674144T3 (pl) Tarcza dozująca i urządzenie do napełniania kapsułek z tarczą dozującą
PL2637704T3 (pl) Radioznakowane ligandy oparte na fenyloimidazolu
IL223707A0 (en) N-hydroxyformamide derivative and medicament containing same
GB201202622D0 (en) Brachytherapy system & in vivo dose detector therefor
EP2857028A4 (en) AGENT CONTAINING ASCORBIC ACID DERIVATIVE AND USE THEREOF
TWI559972B (en) Microparticle and addition agent
TWM403055U (en) Storage type mouse pad
GB201216381D0 (en) New compounds and medical uses
GB201208970D0 (en) New compounds and medical uses
TWM432365U (en) Incense loop disk structure for hold incense, incense and cyclo incense
GB201219720D0 (en) Fish Carrier